Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt  by Elsisi, Gihan H. et al.
Avai lable onl ine at www.sc iencedirect .comV A L U E I N H E A L T H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 3 1 9 – 3 2 72212-1099/$36.00 –
Published by Elsevie
http://dx.doi.org/10.
Conﬂicts of inte
E-mail: gehmast
 Address corresp
Elmanial, Cairo, Egyjournal homepage: www.elsevier .com/ locate /vhr iCONCEPTUAL PAPERRecommendations for Reporting Pharmacoeconomic Evaluations in Egypt
Gihan H. Elsisi, MSc1,, Zoltán Kaló, MSc, MD, PhD2, Randa Eldessouki, MSc, MD3,4, Mahmoud D. Elmahdawy, PharmD5,6,
Amr Saad, MSc, PhD7, Samah Ragab, MPA8, Amr M. Elshalakani, MD, MBA9, Sherif Abaza, MBA10
1Pharmacoeconomic Unit, Central Administration for Pharmaceutical Affairs, Cairo, Egypt; 2Health Economics Research Centre, Eötvös Loránd University,
Budapest, Hungary; 3Scientiﬁc and Health Policy Initiatives, International Society for Pharmacoeconomics and Outcomes Research, NJ, USA; 4Faculty of Medicine,
Fayoum University, Fayoum, Egypt; 5Hospital Pharmacy Administration, Central Administration for Pharmaceutical Affairs, Cairo, Egypt; 6Misr International
University, School of Pharmacy, Cairo, Egypt; 7Pharmacovigilance Center, Central Administration for Pharmaceutical Affairs, Cairo, Egypt; 8Head Technical Ofﬁce,
Central Administration for Pharmaceutical Affairs, Cairo, Egypt; 9Health Economics Unit, Ministry of Health, Cairo, Egypt; 10Market Access, Roche, Cairo, Egypt
A B S T R A C TObjective: Introduction of economic evaluations for pharmaceuticals
or other health technologies can help the optimization of outcomes
from resource allocations. This article aims to provide recommenda-
tions for researchers in presenting pharmacoeconomic evaluations in
Egypt with special focus on pricing and/or reimbursement applica-
tions of pharmaceuticals. Methods: The Minister of Health approved
the initiative of establishing a focus group of decision makers that
included academic and industry experts with experience in health
economics, pharmacovigilance, and clinical pharmacy. The focus
group has reviewed 17 economic evaluation guidelines available on
the Web site of the International Society for Pharmacoeconomics and
Outcomes Research for reporting health economic evaluations. To
develop core assumptions before preparing a draft report, focus group
meetings were held on a regular basis starting June 2012. The
recommendations were developed by using the Quasi-Delphi method,
taking into account current practices and capacities for conducting
pharmacoeconomic evaluations in Egypt. Conclusions: Worldwide,
health care decision makers are challenged to set priorities in an
environment in which the demand for health care services outweighs
the allocated resources. Effective pharmaceutical pricing andsee front matter Copyright & 2013, International S
r Inc.
1016/j.vhri.2013.06.014
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pt.reimbursement systems, based on health technology assessment
(HTA) that encompasses economic evaluations, are essential to an
efﬁcient sustainable health care system. The Egyptian Ministry of
Health and Population was encouraged to establish a pharmacoeco-
nomic unit, as an initial step, for the support of pricing and reim-
bursement decisions. We anticipate that standardization of reporting
would lead to a progressive improvement in the quality of submis-
sions over time and provide the Egyptian health care system with
health economic evidence often unavailable in the past. Therefore,
recommendations for pharmacoeconomic evaluations provide an
essential tool for the support of a transparent and uniform process
in the evaluation of the clinical beneﬁt and costs of drugs that do not
rely on the use of low acquisition cost as the primary basis for
selection. These recommendations will help inform health care
decisions in improving health care systems and achieving better
health for the Egyptian population.
Keywords: economic evaluation, Egypt, recommendations, reporting.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Egypt’s general budget devotes limited amounts to the health
sector. In the period 2008 to 2009, Egypt spent LE 61.4 billion
(Egyptian pounds) on health, which represents 5.9% of the
country’s gross domestic product. Out of the total health care
expenditure, pharmaceutical expenses constitute a large portion,
34%. [1]. In addition, over the past 16 years, the share of out-of-
pocket spending in total health spending has increased dramat-
ically from 51% to 72% [2]. These numbers suggest the increasing
need for optimizing the limited resources available. With the
growing public demand for improving health care services and
reducing the out-of-pocket expenses, economic evaluations ofpharmaceuticals and health technologies are critical for efﬁcient
allocation of the limited resources.
To better allocate resources and with the growing awareness
of the importance of health technology assessment (HTA), the
Ministry of Health and Population (MOHP) established a pharma-
coeconomic unit to support and inform pricing and reimburse-
ment decisions [3]. No economic evaluations guidelines or
standards, however, have been set up yet.
This article provides recommendations based on reviewing
other countries’ national guidelines for economic evaluation as
well as experts’ opinions. Other factors inﬂuencing the feasibility
of conducting such studies in Egypt, including the complexity of
the health sector, the availability of data on health care outcomesociety for Pharmacoeconomics and Outcomes Research (ISPOR).
o conﬂicts of interest with regard to the content of this article.
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macoeconomic evaluations, were put into consideration in devel-
oping these recommendations.Objective
This article aims to provide recommendations for researchers to
present pharmacoeconomic evaluations in Egypt with special
focus on pricing and/or reimbursement applications of pharma-
ceuticals. Policymakers are encouraged to consider these recom-
mendations in developing the national guidelines for the
economic evaluation of pharmaceuticals.Methods
As a self-initiated activity by government personnel, with the
approval of the Ministry of Health at the time, a focus group was
formed. The aim of the focus group was to develop a set of
recommendations and standards for economic evaluation stud-
ies used in applying for reimbursement and coverage to 1)
promote the concept of combining efﬁcacy, safety, effectiveness,
and economic evaluation in the decision-making process; 2)
provide instructions for drug manufacturers: how to supply
information directly to health care decision makers to support
the use of their products; and 3) emphasize that simple assess-
ment of acquisition cost is not a sufﬁcient approach for the
control of overall health care expenditures.
To develop the recommendations, two steps were under-
taken. The ﬁrst step was to review the available national
economic guidelines. It included a review of 17 recently published
national economic evaluation guidelines for conducting and
reporting of economic evaluations (Table 1) that included an
English version available on the Web site of the International
Society for Pharmacoeconomics and Outcomes Research [4].
The second step was to solicit inputs and feedback from key
leaders and stakeholders through focus groups. For a compre-
hensive representation of key stakeholders in health care, focus
groups included decision makers experienced in health econom-
ics, pharmacovigilance, and clinical pharmacy, health providers
as well as researchers and experts selected from both industry
and academia, as shown in Table 2.Table 1 – Focus group members’ information.
Member of Focus
Group
Degree Title
Gihan H. Elsisi MSc Head of Pharmacoeconom
Unit
Randa Eldessouki MSc, MD Director, Scientiﬁc and H
Policy Initiatives/Lectu
Mahmoud D. Elmahdawy PharmD Manager of Hospital Phar
Administration/Part Ti
Lecturer of clinical pha
Amr Saad MSc, PhD Head of Pharmacovigilan
Center
Samah Ragab MPA Director of the Technical
Support Ofﬁce
Amr M. Elshalakani MBBch,
MSc, MBA
Head of Health Economic
Sherif Abaza MBA Market Access & Governm
Affairs ManagerA consensus approach developed by using the Quasi-Delphi
method consisted of an iterative series of meetings and inter-
rogations. Anonymous responses were synthesized into a series
of statements. Then, the synthesized statements were submitted
to the focus group members for comment until convergence or
stasis of opinion was identiﬁed in the third round.
Starting June 2012, focus group meetings were held on a
regular basis to develop core assumptions before preparing a
draft report. The discussions were recorded in written minutes.
The recommendations were developed by consensus approach,
taking into account current practices and capacities for conduct-
ing pharmacoeconomic evaluations in Egypt.Developing Recommendations for Reporting
Pharmacoeconomic Evaluations
Disease and Product Background
Economic evaluations should provide information about the epi-
demiology of the disease and treatment pathways according to
most recent treatment guidelines. Data on the product should
include pharmacological class, proposed dosing regimen, route of
administration, and results of clinical studies performed to date [5].Study Design
The study question should address the needs of the decision
makers by clearly establishing the context of the study. It should
provide details of the study perspective, the proposed product
and its comparator(s), the target population, and the effect on
speciﬁc subgroups where appropriate. Secondary questions that
relate to the primary study question should be clearly stated [6].
Perspective should be relevant to the research question and
adapted to beneﬁts gained by the health care system. The
perspective adopted should maximize the health gain for the
population while representing the most efﬁcient use of the ﬁnite
resources available to the Ministry of Health [7]. It should include
direct medical costs as well as additional costs, savings, or other
beneﬁts when data are available.
The proposed product should be used primarily in the
approved indications with detailed information about itsOrganization Government
Employee
ic Central Administration for
Pharmaceutical Affairs, Cairo, Egypt
Yes
ealth
rer
International Society for
Pharmacoeconomics and Outcomes
Research, NJ, USA/Faculty of
Medicine, Fayoum University, Egypt
No
macy
me
rmacy
Central Administration for
Pharmaceutical Affairs/Misr
International University, Cairo,
Egypt
Yes
ce Central Administration for
Pharmaceutical Affairs, Cairo, Egypt
Yes
Central Administration for
Pharmaceutical Affairs, Cairo, Egypt
Yes
s Unit Ministry Of Health, Cairo, Egypt Yes
ental Hoffmann-La Roche Ltd. Cairo, Egypt No
Table 2 – The national health economic guidelines reviewed by the focus group members.
Title of the document Source, Country Published
Year
Guidelines for the Economic Evaluation of Health Technologies: Canada Canadian Agency for Drugs and Technologies in
Health (CADTH), Canada
2006
Guidelines of Methodological Standards for Pharmacoeconomic
Evaluations in Taiwan
Taiwan Society for Pharmacoeconomics and
Outcomes Research, Taiwan
2006
Prescription for Pharmacoeconomic Analysis: Methods for Cost-utility
Analysis
The Pharmaceutical Management Agency
(PHARMAC), New Zealand
2007
Guidance to Manufacturers for Completion of New Product Assessment
Form
Scottish Medicines Consortium, Scotland 2007
Guide to the Methods of Technology Appraisal National Institute for Health and Clinical
Excellence (NICE), England and Wales
2008
Guidelines for Preparing Submissions to the Pharmaceutical Beneﬁts
Advisory Committee
Pharmaceutical Beneﬁts Advisory Committee
(PBAC), Australia
2008
Guidelines for Pharmacoeconomic Evaluations in Belgium Belgian Health Care Knowledge Center (KCE),
Belgium
2008
Health Technology Assessment Guideline Journal of the Medical Association of Thailand,
Thailand
2008
The Academy of Managed Care Pharmacy Format for Formulary
Submissions
Academy Of Managed Care Pharmacy, United
States
2009
General Methods for the Assessment of the Relation of Beneﬁts to Costs German national institute for quality and
efﬁciency in health care (IQWiG), Germany
2009
Guidelines for conducting Health Technology Assessment Poland Agency for Health Technology
Assessment, Poland
2009
Decree of the Ministry of Social Affairs and Health on applications and
price notiﬁcations made to the Pharmaceuticals Pricing Board–
Appendix: Guidelines for Preparing a Health Economic Evaluation
Ministry of Social Affairs and Health, Finland 2009
Procedure for Clinical and Economic Evaluation of Drug Lists That Are
Submitted for Reimbursement Coverage from Public Health Care
Budget.
ISPOR Russia HTA Regional chapter, Russian
State Medical University, Russian Federation
2010
The Guidelines for Pharmacoeconomic Evaluations of Medicines and
Scheduled Substances
National Department of Health, South Africa 2010
Guidelines for the Submission of a Request to Include a Pharmaceutical
Product in the National List of Health Services
Pharmaceutical Administration, Israel 2010
Guidelines for the Economic Evaluation of Health Technologies in
Ireland
Health Information and Quality Authority, The
National Centre for Pharmacoeconomics,
Ireland
2010
Guidelines on How to conduct Pharmacoeconomic Analyses Norwegian Medicines Agency, Norway 2012
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regulatory status, and the speciﬁc application.
The selection of the comparator has to be justiﬁed. Compara-
tors should be policy relevant; therefore, widely used and reim-
bursed health care technology for a given patient group and
indication is the preferred option. If no such technologies are
reimbursed in the tender list at the time the assessment is
conducted, the investigated product can be compared with the
most frequently used technologies to treat the same patient
groups. If a new product is used as ﬁrst-line, second-line, or
third-line therapy, it should be compared with ﬁrst-, second-, or
third-line therapies, respectively.
The targeted population should include both those who are
insured by the Egyptian health system and those who are unin-
sured. Parameters to deﬁne the population include baseline dem-
ographic characteristics, disease characteristics, treatment setting,
the context of past treatment, and any confounders adjusted [5].
Speciﬁc subgroups should be identiﬁed for those for whom
clinical effectiveness and cost-effectiveness may be expected to
differ from those of the overall population. Stratiﬁed analysis used
to quantify the differences in cost-effectiveness that may exist in
different subgroups is recommended because it may contribute
important information to the ﬁnal advice. The evidence support-
ing the clinical plausibility of the subgroup effect should be fully
documented, including details of statistical analysis [8].Appropriate Pharmacoeconomic Method
The choice of method of analysis depends on the research
question and must be justiﬁed. If the compared health technol-
ogies result in equal health gain, cost minimization analysis is
the preferred analytical approach.
If at least one of the compared health technologies is better
than the other, and the clinical beneﬁt can be aggregated and
interpreted as naturalistic clinical outcomes, cost-effectiveness
analysis (CEA) is the preferred method. CEA, where an inter-
mediate marker is chosen, must have a validated, well-
established link with an important hard end point (e.g., patient
survival, heart attack, and bone fracture) [9]. Because the meas-
ure of primary clinical outcome may differ in different therapeu-
tic areas, CEA cannot be used to compare or rank the cost-
effectiveness of a broad set of products.
If the quality of life of patients is an important clinical
outcome in the treatment course of patients, cost-utility analysis
is the preferred analytical approach. In cost-utility analysis, the
health gain is expressed in a combined single measure of life-
years and health-related quality of life (HRQOL), for example, in
quality-adjusted life-years (QALYs) [10]. Ignoring quality-of-life
differences among products would provide less than complete
data to decision makers to address the health care dilemma of
where to allocate resources [11]. Adherence to the reference case
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ations would facilitate comparability [12].
Time Horizon
In choosing the time horizon, it should be ensured that the chosen
outcome and the resource consumption of the treatment alterna-
tives are observable in this period to reﬂect the course of the disease
and the effects of the interventions. The same time horizon should
be applied to both costs and outcomes [9]. A decision to use a shorter
time frame should be justiﬁed. When extrapolating data beyond the
duration of the study, assumptions regarding future treatment
effects and disease progression should be clearly outlined. Censoring
might be used to account for the incomplete information [13].
Choice of Outcome Measure
The choice of outcome parameters depends both on the indica-
tion and on the research question. Primary outcome measures are
the ﬁrst choice whenever possible. When an intermediate end
point is used, it must have a high degree of predictability of the
ﬁnal end point.
HRQOL is an appropriate outcome indicator for the evaluation of
health status. HRQOL can be measured by using generic question-
naires, disease-speciﬁc questionnaires, or preference-based meas-
ures. If HRQOL is to be included in the study design, this variable
must be measured by validated instruments. The direct use of the
EuroQol ﬁve-dimensional questionnaire, six-dimensional health
state short form (derived from short-form 36 health survey), or
similar generic measures is recommended, because they are easy to
use and interpret and are based on preferences of the general
public. If the use of disease-speciﬁc HRQOL instruments increases
the sensitivity of measurement, mapping of disease-speciﬁc HRQOL
results with the EuroQol ﬁve-dimensional questionnaire or similar
generic measures can be useful to translate the ﬁndings into QALYs.
Information on the changes in the health state should be
reported directly by the patient or the caregiver. A valuation of
these changes in the health state should then be reported for the
general population. The outcome parameter chosen must be
sensitive, valid, and consistent [14].
Synthesis of Clinical and Economic Evidence
Evidence synthesis has to be based on objective, systematic, and
reproducible search criteria. Estimation of health gain must be
based on scientiﬁc literature review and/or results of primary
data collection, and the best available evidence should be
considered. Meta-analysis based on large randomized controlled
trials is the highest hierarchy of evidence with the heterogeneity
of data accounted for. If compared drug therapies differ in
adherence or persistence of patients, then these factors should
be incorporated in calculating the relative effectiveness. In case
of orphan drugs where randomized controlled clinical studies
have not been conducted, the results of uncontrolled clinical
studies can be accepted, including studies with small sample
size. All product safety data need to be included whether from
clinical studies or from national and foreign pharmacovigilance
centers and patient registries with attention given to those that
differ substantively among the products being compared [15].
Economic evidence should be synthesized from systematic
review of the local data sources and the best available evidence.
Costs Determination
Resource use data should be obtained mainly from primary data
collection (e.g. health care providers or non-interventional stud-
ies) from Egypt; if not available, secondary data sources such as
local administration, accounting data, or patient chart review datacan be used. Ofﬁcial sources of unit cost data for products
(e.g., tender lists) are preferable. In the absence of a published
tender list price, the price submitted by a manufacturer for a
product may be used. The quality, validity, relevance, and gen-
eralizability of local data should be clearly described. Both
estimated consumption of resources and their unit prices must
reﬂect real-world settings in Egypt because relative and absolute
price levels differ among countries [16].
Resource use and costs should be identiﬁed, measured in their
natural units and values [17]. The primary perspective for these
studies is the overall health care services. Therefore, the resour-
ces that should be considered are direct medical costs, which
include drugs, medical devices, medical services including pro-
cedures, laboratory, or diagnostic tests, hospital services and
emergency department visits, and primary care visits. Other
direct nonmedical and indirect costs paid by patients, including
lost productivity costs, might be included only in the sensitivity
analysis. If indirect costs are included in the analysis, the ration-
ality of the costs and how they are estimated should be
explained. Current and future costs arising as a consequence of
a product, and occurring during the speciﬁed time frame of the
study, should also be included. Mean values should be used.
Different costs or costs of the same resources that are used in
different quantities should be included in the analysis [18].
Out of the two general approaches to determine costs, micro-
costing and macro-costing, macrocosting is preferred [19]. The
source of cost data must be reported in detail. Data should be the
most recently available, with the cost year speciﬁed. Retrospective
input costs should be inﬂated to the most recent calendar year by
using the Consumer Price Index for health [20]. The drug cost used
should reﬂect the formulation and pack size that gives the lowest
cost. For drugs available in the outpatient pharmacies, the full
public price should be used for calculating costs. For hospital
products, the wholesale price should be used for cost calculations.
Future costs should be calculated at constant current costs; there-
fore, results are not subject to uncertainty in future inﬂation rates.
Modeling
Economic modeling based on prospectively collected data is the
preferred method by decision makers in an increasing number of
countries to aggregate the expected costs and health effects for
all options relating to appropriate population and subpopula-
tions, based on the full range of existing evidence [21]. The major
aim of applying modeling techniques is to aggregate short- and
long-term outcomes in the most appropriate time horizon.
The results of economic modeling studies presented should take
into account the following requirements: 1) the model should be
described in detail and should correspond to real practice of patient
management; 2) the model should be as simple as possible, and
easily understood; and 3) to facilitate assessment of the outputs of a
model, full documentation of the structure, data elements, and
validation of the model should be addressed in a clear manner,
with justiﬁcation provided for the options chosen and presented
through diagrams (e.g., decision trees and Markov models) [22].
In addition, the model should be adapted to exclude clinical
events not expected to differ among the comparator products
[20]. For state transition models, such as Markov models, the
cycle length should be sufﬁciently short to ensure that multiple
changes in disease, treatment decisions, or costs do not occur
within a single cycle. Heterogeneity in the population should be
accounted by disaggregating the population into clinically plau-
sible subgroups that require different structural assumptions.
The internal validity of the model should be tested before using
to ensure that the model is robust. The external validity should
be tested by comparison of the results with those generated by
other models and explaining differences if they exist.
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Discounting should be made according to the time horizon. Any
costs or outcomes occurring beyond 1 year should be discounted
by using standard methods [19]. For comparability of results
across evaluations, it is important that a common discount rate
is used. Because constant prices and outcomes are used in the
economic evaluation, there is no need to take into account
inﬂation in the discount rate. A real discount rate of 3.5% per
year should be used for both costs and health gains. The discount
rate should be varied from 2% to 6% in the sensitivity analysis.
Uncertainty
Data for a health economic analysis are derived from various
sources, and this may be incomplete and affected by uncertain-
ties. In a sensitivity analysis, critical component(s) in the calcu-
lation should be varied through a relevant range or from the
worst case to the best case, and the results recalculated [13].
Probabilistic sensitivity analysis (PSA) is an appropriate
method for exploring uncertainty around the true mean values
of cost and efﬁcacy inputs in decision-analytic modeling. In PSA,
however, probability distributions are applied by using speciﬁed
plausible ranges for the key parameters rather than the use of
varied point estimates for each parameter. Its results are difﬁcult
to interpret for decision makers, while the stochastic approach,
such as deterministic sensitivity analysis (DSA), examines how
parameter variables (included as point estimates) affect the
model output [23]. We propose, given the difﬁculty in interpreting
the PSA, that DSA should be required, while PSA remains
optional.
To avoid potential bias and uncertainty that arise from the
modeling process, assumptions about the model structure should
be clearly stated and justiﬁed and their impact on cost-
effectiveness explored though a series of plausible scenario
analyses so that whether the study results will be changed can
be observed. All choices and the ranges of the parameters, and
the method used in sensitivity analysis, should be clearly
explained.
Present Study Results
Total costs and health outcomes must be reported separately,
and the aggregated result be explained. All parameters used in
the estimation of clinical effectiveness and cost-effectiveness
should be itemized in a tabular form with data sources trans-
parently. Negative results should be reported. Incremental cost-
effectiveness ratio has to be calculated, unless one of the
compared health technologies dominates the other one. In
addition, the potential impact of the introduction of the new
treatment on the society needs to be assessed [24].
Where more than two products are being compared, the
results should be presented in the order of increasing costs and
the incremental cost-effectiveness ratio calculated by comparing
each product with the one above it, excluding those products that
are dominated. Equity issues, affordability, and resource con-
straints should be considered in judging the cost-effectiveness of
a product for reimbursement [20].
Tornado diagrams are useful tools to display DSA. If PSAs are
performed, the probability that the intervention is cost-effective
at a range of threshold values should be reported and the data
should be displayed graphically to facilitate the uncertainty
interpretation [9].
Equity and Generalizability Issues
To meet the needs of the decision makers, an attempt should be
made to include equity considerations in the study report. Theequity assumption of the basic case in economic evaluations
means that all patients should have a fair participation oppor-
tunity and obtain the expected treatment outcomes.
To determine equity in economic evaluation, we propose that
all lives, life-years, or QALYs should be valued equally, regardless
of the age, gender, or socioeconomic status of individuals in the
population [12]. The equity assumption should be included in
every model and analytical method of economic evaluations and
must be clearly stated.
Analysts must consider two speciﬁc areas of concern regard-
ing the generalizability of clinical and economic data in the
assessment of technologies. The ﬁrst area of concern is the
extent to which the clinical efﬁcacy data are representative of
the likely effectiveness and similarly the extent to which eco-
nomic data are representative of the costs and resource utiliza-
tion [8]. The second area of concern is the generalizability of the
economic and clinical data across different patient ages and
genders as well as regional differences in health care practice
within Egypt. These areas of concern should be identiﬁed and
discussed, and the likely effect on the results and conclusions of
the report should be highlighted [25].Discussion
There is an increasing need for justiﬁcation of resource alloca-
tions and policy decisions, especially with the scarcity of public
resources. Fig. 1 shows that among all middle-income countries
in the region, Egypt invests a smaller proportion of its gross
domestic product on health care [1]. Investments in economic
evaluation studies and development of pharmacoecomic guide-
lines and expertise will help in allocating these limited resources
in the most efﬁcient way to improve health care services.
The current reimbursement decisions in Egypt are based on
the lowest price after clinical review and approval of efﬁcacy and
safety of the medication by the Procurement Technical Commit-
tee. The Procurement Technical Committee reviews all MOHP
hospitals and primary care units’ needs of medications and
applications submitted by drug manufacturers. It then decides
whether this medication is to be listed or not, according to
pharmacokinetics, pharmacodynamics, safety, and efﬁcacy.
Then, the applications go to the Committee for Financial Offers
at the MOHP to review the ﬁnancial issues and decide which drug
manufacturer or wholesaler, the one that presents the lowest
price for each active ingredient (medication), is to get reimburse-
ment. Drug manufacturers or wholesalers who submitted iden-
tical price levels for the same active ingredient are given
reimbursement by an equal process. Fig. 2 presents the decision
makers and inﬂuencers in the Egyptian pricing and reimburse-
ment decision-making processes [26].
There is a growing need to incorporate high-quality economic
evaluation studies into the reimbursement decision-making
process to adequately evaluate clinical and economic beneﬁts
of medications in addition to the assessment of their acquisition
costs. These evaluations will improve decision making with
prioritizing our resources, which results in reducing our huge
expenditure on pharmaceuticals and save these resources to be
allocated to other cost-effective health technologies. In Egypt,
there is no limited budget that should be allocated for drug
coverage only but is allocated to the whole health sector.
The submission of an economic evaluation is currently rec-
ommended in Egypt. And an economic evaluation guideline to
standardize the process and provide a transparent and uniform
approach was approved by the Ministry of Health. There is a big
chance that these recommendations will be implemented in
Egypt. Policymakers are encouraged to consider these
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Fig. 1 – Egypt in comparison with other middle-income countries in overall health care spending as percentage of gross
domestic product. Data from USAID [1].
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economic evaluation of pharmaceuticals.
The Canadian guidelines reported that by providing standards
for conducting and reporting of economic evaluations, the cur-
rent limitations of evaluations can be addressed and lead to
better study [9]. It is important to note that the standardization of
reporting and other policies in the United States shared in the
bulk of the estimated $2 trillion savings [27]. We anticipate that
the standardization of reporting would lead to a progressive
improvement in the quality of submissions over time and provide
the Egyptian health care system with data often unavailable in
the past.Fig. 2 – The Egyptian pricing and reimbursement decision-makin
decision inﬂuencer bodies; bold arrows, required step in the de
decision.In developing those recommendations, we chose to build on
the learning experience from other countries and modify and
adapt the knowledge acquired to ﬁt the Egyptian setting. In doing
so, duplication of efforts and use of resources much needed
elsewhere are avoided. As a rule, certain elements of HTA reports
are transferable, but adjustment to local data is absolutely
necessary [16]. Copying recommendations based on international
HTA without local adjustment may do more harm than good.
Putting this into consideration, our recommendations were tail-
ored to the current settings and environment in Egypt while using
the current guidelines as an initial benchmark. Our starting point
is built on many years of experiences and expertise worldwide.g processes [26]. Bold boxes, decision-making bodies; boxes,
cision-making process; arrows, may or may not affect
Table 3 – Key elements of the recommendations for reporting pharmacoeconomic evaluations in Egypt.
Key elements The Egyptian recommendations Differences/
similarities across
the national
guidelines
reviewed
Rationale for inclusion in the Egyptian
setting
Perspective It should be relevant to the research
question and adapted to beneﬁts gained
by the health care system.
Common It is a common agreed-upon element that
captures all the beneﬁts when data are
available representing the most efﬁcient
use of the ﬁnite resources.
Indication It should be used in the approved
indications.
Common According to the Egyptian Ministry of Health
regulations, the use of the product in
unapproved indications is forbidden.
Choice of
comparator
Comparators should be policy relevant. The
widely used and reimbursed health care
technology for a given patient group is the
preferred option.
Different Because of policy-related problems such as
drug supply shortage, we have to use the
available technologies.
Target
population
Both those who are insured and uninsured
by the Egyptian health care system.
Different Because of the existing widespread
uninsured population that is covered by
other forms of health coverage, there is a
need to assess the effectiveness among
different categories of access to health
care.
Subgroup
analysis
Only for those for whom clinical
effectiveness and cost-effectiveness may
be expected to differ from that of the
overall population.
Common When a distinct group differs from the
overall population, a subgroup analysis is
essential to reﬂect the actual clinical
beneﬁt and provide an accurate estimate
of the cost-effectiveness of the therapy
across all population groups to better
inform decision on reimbursement.
Preferred
analytical
technique
Any of CMA, CEA, and CUA considered. Different It depends on the research question. When
the clinical beneﬁt is interpreted as
naturalistic clinical outcomes, CEA is the
preferred method while CUA is the second
option because the concept of using
QALYs might not be well understood by
the majority of decision makers.
Time horizon It should be ensured that the chosen
outcome and the resource consumption of
the treatment alternatives are observable
in this period.
Common To accurately reﬂect the course of the
disease and the total effects of the
interventions.
Choice of
outcome
measure
Primary outcome measures are the ﬁrst
choice. CEA, where the intermediate
marker is chosen, must have a validated,
well-established link with an important
hard end point. In CUA, outcomes are
measured in QALYs gained.
Common It depends both on the indication and on the
research question.
Preferred
method to
derive utility
The direct use of the EQ-5D questionnaire,
SF-6D, or similar generic measures is
recommended.
Common They are easy to use and interpret and are
relevant to the Egyptian public
educational level and preferences. After a
period of time allowing knowledge
building and according to the learning
curve, more sophisticated instruments
might be considered.
Synthesis of
clinical and
economic
evidence
Evidence synthesis has to be based on
objective, systematic, and reproducible
search criteria. The results of meta-
analysis are preferable with the
heterogeneity of data accounted for.
Economic evidence should be synthesized
from systematic review of the local data
sources and the best available evidence.
Common Meta-analysis based on large randomized
controlled trials is the highest hierarchy of
clinical evidence and is recommended for
clinical beneﬁt evidence. However, econo-
mic beneﬁt evidence is nontransferable
among the countries and should be
obtained from local data sources and the
best available evidence.
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Table 3 – continued
Key elements The Egyptian recommendations Differences/
similarities across
the national
guidelines
reviewed
Rationale for inclusion in the Egyptian
setting
Costs to be
included
Direct medical costs as well as additional
costs, savings, or other beneﬁts when data
are available.
Different In most cases, data and information on
indirect costs are lacking in Egypt;
therefore, direct costs estimation is
recommended.
Sources of
costs
Primary data collection; if unavailable,
secondary data sources can be used such
as local administration, accounting data,
and patient chart review. Ofﬁcial sources
of unit cost data for products (e.g., tender
lists) are preferable.
Common Both estimated consumption of resources
and their unit prices must reﬂect real-
world settings in Egypt because relative
and absolute price levels differ among
countries.
Modeling Modeling options include decision trees and
Markov models. The model should be
described in detail and should correspond
to real practice of patient management.
Common These models are easy to use, interpret, and
aggregate the expected costs and short-
and long-term outcomes captured in the
most appropriate time horizon relating to
the Egyptian population and subpopula-
tions.
Discounting
costs and
outcomes
A discount rate of 3.5% per year should be
used for costs and outcomes.
Common Because constant prices and outcomes are
used in the economic evaluation, there is
no need to take into account inﬂation in
the discount rate.
Uncertainty Critical component(s) in the calculation
should be varied through a relevant range
or from the worst case to the best case.
DSA should be required, while PSA
remains optional.
Different With the current level of knowledge, results
of PSA are difﬁcult to interpret by
personnel reviewing the studies for
coverage decisions.
Equity issues All lives, life-years, or QALYs should be
valued equally, regardless of the age,
gender, or socioeconomic status of
individuals in the population.
Common All patients should have a fair participation
opportunity and obtain the expected
treatment outcomes.
Generalizability The generalizability and the extent to which
the clinical efﬁcacy data and the
economic data are representative should
be identiﬁed and discussed.
Common Because of the presence of wide regional
differences in health care practice among
urban and rural areas, generalizability of
the studies should be discussed in detail.
Presenting
results
Total costs and health outcomes must be
reported separately, and the aggregated
result be explained. ICER has to be
calculated. The probability that the
intervention is cost-effective at a range of
threshold values should be reported and
displayed graphically.
Common Detailed information should be provided to
facilitate the interpretation of results,
thus allowing for a more transparent and
uniform process for the ﬁnal coverage
decision.
CEA, cost-effectiveness analysis; CMA, cost minimization analysis; CUA, cost-utility analysis; DSA, deterministic sensitivity analysis; EQ-5D,
EuroQol ﬁve-dimensional; SF-6D, six-dimensional health state short form (derived from short-form 36 health survey); ICER, incremental cost-
effectiveness ratio; PSA, probabilistic sensitivity analysis; QALYs, quality-adjusted life-years.
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reviewed were included in the recommendations. Other key
elements differed between the various guidelines such as the
choice of comparator, preferred analytical technique, target
population, costs to be included, and uncertainty. Through a
consensus approach between all focus group members
for these elements, we recommended the best ﬁt to Egyptian
settings that are applicable to the current Egyptian environ-
ment. A summary of the key elements of the recommendations
and the rationale for their inclusion within the Egy-
ptian setting are presented in Table 3 highlighting the elements
that were common across all guidelines and the ones that
varied.HTA implementation in Egypt, however, is signiﬁcantly chal-
lenged by the diversity and heterogeneity of the health care
system, limited tradition for national treatment guidelines, and
limited availability of epidemiological, health outcomes, and cost
data. Data for economic evaluations are low quality, region and
provider speciﬁc, unavailable in electronic records, and, in most
cases, not updated. So, the common opinion is “HTA cannot be
implemented in Egypt.” In fact, there are no perfect data for
health care research; we have to assess realistically how wrong
they have to be not to be considered useful. Having some data is
better than having no data at all; conducting pharmacoeconomic
evaluations and outcomes research in Egypt would also greatly
improve the quality of current data.
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implementation of these recommendations on reporting in
future economic evaluations in a manner similar to Consolidated
Health Economic Evaluation Reporting Standards (CHEERS):
ISPOR Task force report [28]. As methods for the conduct of
economic evaluation continue to evolve, it will also be important
to revisit our recommendations. These recommendations were
presented to the Assistant Minister of Health, and initial steps
required to start building the capacity of the pharmacoeconomic
unit are underway. A young generation of government personnel
is enthusiastic to enter this ﬁeld; recent graduates from the ﬁrst
health economic diploma program in the Middle East are keen to
facilitate the implementation of HTA in Egypt.Conclusions
Worldwide, health care decision makers are challenged to set
priorities in an environment in which the demand for health care
services outweighs the allocated resources [29]. Effective pharma-
ceutical pricing and reimbursement systems, based on HTA that
encompasses economic evaluations, are essential to an efﬁcient
sustainable health care system [30]. The MOHP was encouraged to
establish a pharmacoeconomic unit, as an initial step, for the
support of pricing and reimbursement decisions. We anticipate
that the standardization of reporting would lead to a progressive
improvement in the quality of submissions over time and provide
the Egyptian health care system with health economic evidence
often unavailable in the past. Therefore, recommendations for
pharmacoeconomic evaluations provide an essential tool for the
support of a transparent and uniform process in the evaluation of
the clinical beneﬁt and costs of drugs that do not rely on the use of
low acquisition cost as the primary basis for selection. Eventually,
these recommendations will help inform the health care decisions
in improving health care systems and achieving better health for
the Egyptian population.
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